Here’s Why that Race-Sex Abortion Ban Bill is So Discriminatory
By Sital Kalantry,
Women's eNews
| 04. 19. 2016
Untitled Document
You may have never heard of the word PRENDA. But the U.S. House of Representatives Judiciary Committee held a hearing on it on April 14.
PRENDA stands for the Prenatal Nondiscrimination Act of 2016.
If enacted, the bill would subject medical professionals to up to five years imprisonment for performing an abortion on a woman who wants to abort the fetus because of its race or sex. A similar bill was defeated in the House of Representatives in 2012.
Sex-selective bans have been introduced in over half of the state legislatures in the United States and have been passed by eight of those legislatures. But in addition to banning sex-selective bans, this federal bill reaches further, banning race-selective abortions as well.
Arizona is the only state to ban race-selective abortions. Eight other states and the United States Congress have considered and rejected race-selective bans.
The rationale behind sex-selective abortion bans is tied to countries such as India and China.It is widely known that there is a male-surplus in India and China and it is attributed to...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...